A Randomized, Double-blind, Placebo-controlled, Global Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)

Early Alzheimer’s Disease

Change from baseline at Week 76 in brain tau deposition, as measured by tau positron emission tomography (PET)

Change from baseline at Week 76 in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score, Change from baseline at Week 76 in integrated Alzheimer’s Disease Rating Scale (iADRS) score, Change from baseline at Week 76 in Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS- Cog14) score, Change from baseline at Week 76 in Mini Mental State Examination (MMSE) score, Change from baseline at Week 76 in Alzheimer’s Disease Cooperative Study-instrumental Activities of Daily Living scale (ADCS-iADL) score

No related papers found yet.

Belgium, Spain, Sweden